Relmada Therapeutics to hold one-on-one investor meetings at Wells Fargo Healthcare ConferencePUBT·Sep 1 at 12:02 PMRLMD+1.37%WFC+0.87%
6,391,328 Shares in Relmada Therapeutics, Inc. $RLMD Purchased by Spruce Street Capital LPMarket Beat·Aug 25 at 09:37 AMRLMD+1.37%GS-D+0.43%
Equities Analysts Issue Forecasts for RLMD Q3 EarningsMarket Beat·Aug 11 at 11:42 AMRLMD+1.37%GS-D+0.43%
Relmada Therapeutics (NASDAQ:RLMD) Stock Price Down 6.8% - Time to Sell?Market Beat·Aug 7 at 04:40 PMRLMD+1.37%
Relmada publishes investor presentation highlighting NDV-01 program for non-muscle invasive bladder cancerPUBT·Aug 6 at 09:41 PMRLMD+1.37%
Relmada Q2 FY26 net loss widens to $12.9 million; R&D expense rises to $8.4 millionPUBT·Aug 6 at 08:30 PMRLMD+1.37%
ADAR1 Capital Management LLC Grows Stock Position in Relmada Therapeutics, Inc. $RLMDMarket Beat·Jul 29 at 07:13 AMRLMD+1.37%JHG0.00%
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Sees Significant Growth in Short InterestMarket Beat·Jul 17 at 11:40 AMRLMD+1.37%
